AzTrials
AzTrials

Stage, Pancreatic CancerMPMNCT02900950

Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer

A study testing Multicolour inking specimens and Monocolour inking specimens in people with Stage, Pancreatic Cancer and Neoplasm, Residual, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B (monocolour inking). Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Multicolour inking specimens and Monocolour inking specimens
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
1 siteItaly
Study dates
Jun 2012to Jan 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • medical history without previous pancreatic resection or pancreatic cancer
  • written consent

Who cannot join

  • patients previously treated with chemotherapy radiotherapy or chemoradiotherapy for pancreatic cancer
  • patients with diagnostic doubts of chronic pancreatitis, serous cystic tumours, intraductal papillary mucinous tumours or neuroendocrine tumours
  • patients unresectable at laparotomy
  • patients who had undergone other pancreatic resections (total or subtotal pancreatectomy).

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • S.Orsola-Malpighi Hospital, University of Bologna

    Bologna, Bologna, 40138

Other trials in Italy

About this study

Official title: Multicolour Versus Monocolour Inking Specimens After Pancreaticoduodenectomy for Periampullary Cancer: a Single Center Prospective Randomised Clinical Trial.

A single-centre, randomised clinical trial of patients affected by periampullary cancer who underwent pancreaticoduodenectomies which included two different types of specimen margination: arm A (multicolour inking) and arm B (monocolour inking). The randomisation of the specimen was made after the resection, blinded for the surgeons involved in the operation. The primary endpoint was the overall R1 resection rate and its difference between the two arms. The secondary endpoints were the R1 resection rate in each margin and its difference between the two arms, and the impact of margin status on survival. A sample size of 18 patients was required.

Read the detailed description

This study was a single-centre, prospective, controlled, open, parallel group, randomised clinical trial, conducted in the tertiary referral University Centre of S.Orsola-Malpighi Hospital, Bologna, Italy, from June 2012 to January 2016, which enrolled patients affected by periampullary cancer who underwent pancreaticoduodenectomy (PD). All patients with suspected periampullary cancer were enrolled in the study, but only patients who underwent pancreaticoduodenectomy were randomised and allocated to a multicolour inking specimen (arm A, experimental) or a monocolour inking (arm B, control) after specimen was taken out from the operative field. The analysis regarded only the specimens of the patients who underwent PD in which the final pathologic report showed a diagnosis of invasive periampullary cancer (pancreatic, ampullary and distal bile duct).

After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. In the multicolour arm, the surfaces/margins inked were the following: Anterior surface of the pancreas (yellow); Posterior surface of the pancreas (orange); Superior mesenteric/portal vein groove (blu); Superior mesenteric artery margin (retroperitoneal margin) (red); Transection margin of the bile duct (green).The trans-section pancreatic and gastric margins were not inked.

In the monocolour arm, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist. In both arms of treatment, the macroscopic evaluation and slicing of the surgical specimen followed the Leeds Pathology Protocol (LEEPP), and seven margins, which included the anterior, posterior, superior mesenteric /portal vein groove, superior mesenteric artery, bile duct, pancreatic neck and stomach margins, were examined. The primary endpoint was to evaluate the overall R1 resection rate and its difference between multicolour (arm A) and monocolour (arm B) inking of the specimen. The secondary endpoints were to evaluate the R1 resection rate in each margin: anterior and posterior surfaces of the pancreatic head; superior mesenteric/portal vein groove; superior mesenteric artery margin; transection pancreatic and bile duct margins, and its difference between the two arms compared. Finally, the impact of the margin status on survival was considered for each margin and type of periampullary tumours.

Calculation of the sample size was based on the literature assumption that the overall incidence rate expected of R1 ranged from 10 to 76% while it increased to 81-85% when a standardised pathological technique and margination with multicolour inking, as described in arm A, was performed. To detect a difference in R1 rate between these values with a 5% alpha-error and a 80% beta-error at a two-sided 0.05 significance level, a sample size of 18 patients was required for each group. In relation to the fact that the patients were often randomised without a preoperative biopsy, and that following current literature the 5-13% of the presumed malignancies were benign, it was decided to randomise 25 patients in order to avoid a sample size smaller than expected. The sample size calculation was carried out using PS Power and Sample Size Calculation software (Department of Biostatistics; Vanderbilt University; Nashville, TN, USA).

Being tested
Multicolour inking specimens, Monocolour inking specimens
Keywords
cancer, resection margin, pathology, pancreas
Medical subject headings
Pancreatic Neoplasms, Neoplasm, Residual, Neoplasms, Margins of Excision

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multicolour inking specimensProcedure or surgery

  • Monocolour inking specimensProcedure or surgery

Study groups in NCT02900950
Study groupRoleWhat they receive
Arm A-Multicolour inking specimenExperimentalAfter performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following: 1. Anterior surface of the pancreas (yellow); 2. Posterior surface of the pancreas (orange); 3. Superior mesenteric/portal vein groove (blu); 4. Superior mesenteric artery margin (retroperitoneal margin) (red); 5. Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked.
Receives: Procedure: Multicolour inking specimens
Arm B-Monocolour inking specimenOtherIn arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
Receives: Procedure: Monocolour inking specimens

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate overall microscopic resection margins involvement (R1 rate) after pancreaticoduodenectomy for periampullary cancer.

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  2. Evaluate R1 rate differences between multicolour and monocolour inking of the specimen

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

Secondary outcomes (8)
  1. Evaluate R1 resection rate in anterior surface of the pancreatic head.

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  2. Evaluate R1 resection rate in posterior surface of the pancreatic head.

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  3. Evaluate R1 resection rate in superior mesenteric/portal vein groove

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  4. Evaluate R1 resection rate in superior mesenteric artery margin

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  5. Evaluate R1 resection rate in pancreatic transection margin

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  6. Evaluate R1 resection rate in common bile duct margin

    Microscopic margin involvement (R1) was defined as a distance of the tumour from the resection margin of ≤1 mm.

    Measured: At the time of pathological examination

  7. Disease Free Survival and Overall Survival of the participants

    Disease Free Survival and Overall Survival of the participants are measured using Kaplan-Meier curves.

    Measured: Through study completion, an average of 6 months

  8. Relation between Disease Free Survival and Overall Survival of the participants and R status

    Disease Free Survival and Overall Survival of the participants are measured using Kaplan-Meier curves and divided in subgroups related to their margin status (R0 versus R1).

    Measured: Through study completion, an average of 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2016 (estimated)
  2. Study startJun 2012
  3. Primary completionJan 2016
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02900950
Sponsor's protocol ID
MPM-DCP
Acronym
MPM
Status last verified
Sep 2016
First submitted
1 Sep 2016
Last updated
15 Sep 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Multicolour inking specimens and Monocolour inking specimens in people with Stage, Pancreatic Cancer and Neoplasm, Residual, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate overall microscopic resection margins involvement (R1 rate) after pancreaticoduodenectomy for periampullary cancer. (time frame: At the time of pathological examination). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in